Significance of ferritin expression in formation of malignant phenotype of human breast cancer cells

Experimental Oncology

Volumn 36, Issue 3, 2014, Pages 179-183

  Chekhun, S V ^a   Lukyanova, N Y ^a   Shvets, Y V ^a   Burlaka, A P ^a   Buchynska, L G ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

"Free iron"; Basal subtype; Breast cancer; Cell lines; Ferritin; Luminal subtype; MiRNA 200b; ROS; SOD

Indexed keywords

FERRITIN; MICRORNA; MICRORNA 200B; REACTIVE OXYGEN METABOLITE; STEROID HORMONE; SUPEROXIDE DISMUTASE; FTH1 PROTEIN, HUMAN; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; FERRITIN HEAVY CHAIN; FLOW CYTOMETRY; HEAVY CHAIN; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; BREAST TUMOR; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

BREAST NEOPLASMS; FEMALE; FERRITINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICRORNAS; PHENOTYPE; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TUMOR CELLS, CULTURED;

EID: 84907564638     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cancer in Ukraine, 2011-2012. Morbidity, mortality, activity of oncological service: Bulletin of National Cancer Register of Ukraine. Fedorenko ZP, Mikhailovich YuYo, Gulak LO, et al.; IB Shchepotin, ed. Kyiv: 2013;14:120 p.
2. Lips EH, Mulder L, De Ronde JJ, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 2013;140:63-71.
3. Boyle DP, McCourt CM, Matchett KB, et al. Molecular and clinicopathological markers of prognosis in breast cancer. Exp Rev Mol Diagnost 2013;13:481-98.
4. Langlands FE, Horgan K, Dodwell DD, Smith L. Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol 2013;86:20120601.
5. Guiu S, Michiels S, André F, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012;23:2997-3006.
6. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-8.
7. Chekhun S, Bezdenezhnykh N, Shvets J, Lukianova N. Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Exp Oncol 2013;35:174-9.
8. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nature Rev Cancer 2013;13:342-55.
9. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular diferentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010;207:731-50.
10. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014;19:16 4-74.
11. Linder MA. Mobilization of stored iron in mammals. Nutrients 2013;5:4022-50.
12. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochem Biophys Acta 2013;1836:245-54.
13. Michel FM, Hosein HA, Hausner DB, et al. Reactivity of ferritin and the structure of ferritin-derived ferrihydrite. Biochim Biophys Acta 2010;1800:871-85.
14. Lamy PJ, Durigova A, Jacot W. Iron homeostasis and anemia markers in early breast cancer: Iron and breast cancer. Clin Chim Acta 2014;434:34-40.
15. Alkhateeb AA, Connor JR. Nuclear ferritin: A new role for ferritin in cell biology. Biochim Biophys Acta 2010;1800:793-7.
16. Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: past, present and future. Biochim Biophys Acta 2010;1800:760-9.
17. Orino K, Watanabe K. Molecular, physiological and clinical aspects of the iron storage protein ferritin. Vet J 2008;178:191-201.
18. Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012;5:981-90.
19. Ulbrich EJ, Lebrecht A, Schneider I, et al. Serum parameters of iron metabolism in patients with breast cancer. Anticancer Res 2003;23:5107-9.
20. Shpyleva SI, Tryndyak VP, Kovalchuk O, et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011;126:63-71.
21. McCelland RA, Wilson D, Leake R. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991;27:711-5.
22. Pate KT, Rangel NA, Fraser B, et al. Measuring "free" iron levels in Caenorhabditis elegans using low-temperature Fe (III) electron paramagnetic resonance spectroscopy. Anal Biochem 2006;358:199-207.
23. Ogura R, Ueta H, Sugiyama M, Hidaka T. Distribution of superoxide dismutase activity in the epidermis: measurement with electron spin resonance spin trapping. J Invest Dermatol 1990;94:227-9.
24. Huang X. Does iron have a role in breast cancer? Lancet Oncol 2008;9:803-7.
25. Linder MA. Mobilization of stored iron in mammals: a review. Nutrients 2013;5:4022-50.
26. Marques O, Martins Da Silva B, Porto G, Lopes C. Iron homeostasis in breast cancer. Cancer Lett 2014;347:1-14.
27. Moore AB, Shannon J, Chen C, et al. Dietary and stored iron as predictors of breast cancer risk: a nested casecontrol study in Shangai. Int J Cancer 2009;125:1110-7.
28. Cozzi A, Corsi B, Levi S, et al. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem 2000;275:25122-9.
29. Chekhun VF, Lukyanova NY, Burlaka AP, et al. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol 2013;43:1481-6.
30. Antipova SV, Shepil OV, Lukyanova NY, Chekhun V. F. Relation of ferritin level in serum nd tumour tissue to sensitivity to neoadjuvant chemotherapy in breast cancer patients. Onkologiya 2013;15:204-9 (in Ukrainian).
31. Chekhun VF, Shepil OV, Lukyanova NY, et al. Method of chemosensitivity prognosis to neoadjuvant therapy in breast cancer patients. Patent No 84044, 10.10.2013. Bulletin No19/2013 (in Ukrainian).